These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37105270)

  • 1. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
    Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
    Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibitors for the therapy of atopic dermatitis.
    Traidl S; Freimooser S; Werfel T
    Allergol Select; 2021; 5():293-304. PubMed ID: 34532638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
    Shih PY; Li CJ; Yong SB
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
    Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
    J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.
    Zhang Y; Jiang G
    Front Immunol; 2024; 15():1341632. PubMed ID: 38444845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].
    Lauffer F; Biedermann T
    Dermatologie (Heidelb); 2022 Jul; 73(7):520-528. PubMed ID: 35608635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrocitinib for the treatment of atopic dermatitis.
    Crowley EL; Nezamololama N; Papp K; Gooderham MJ
    Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results.
    Szalus K; Trzeciak M; Nowicki RJ
    Microorganisms; 2020 Nov; 8(11):. PubMed ID: 33172122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK inhibitors in the treatment of atopic dermatitis.
    Chovatiya R; Paller AS
    J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
    Zhang L; Wang L; Jiang X
    Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
    De SK
    Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.